Spots Global Cancer Trial Database for everolimus placebo
Every month we try and update this database with for everolimus placebo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | NCT03312738 | Advanced Breast... | Everolimus Exemestane Everolimus Plac... | 18 Years - | Novartis | |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | NCT00790036 | Diffuse Large B... | Everolimus Everolimus Plac... | 18 Years - | Novartis | |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | NCT03312738 | Advanced Breast... | Everolimus Exemestane Everolimus Plac... | 18 Years - | Novartis | |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | NCT00790036 | Diffuse Large B... | Everolimus Everolimus Plac... | 18 Years - | Novartis | |
| Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | NCT00879333 | Advanced Gastri... | Everolimus Everolimus plac... Best Supportive... | 18 Years - | Novartis | |
| A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | NCT03312738 | Advanced Breast... | Everolimus Exemestane Everolimus Plac... | 18 Years - | Novartis | |
| Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | NCT00879333 | Advanced Gastri... | Everolimus Everolimus plac... Best Supportive... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
